Production (Stage)
Regen BioPharma, Inc.
RGBP
$0.07
$0.028970.32%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.51% | 0.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.51% | 0.51% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -0.51% | 0.51% | |||
| SG&A Expenses | 7.31% | -16.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.36% | -12.75% | |||
| Operating Income | 28.94% | 20.00% | |||
| Income Before Tax | -94.56% | -103.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -94.56% | -103.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -94.56% | -103.61% | |||
| EBIT | 28.94% | 20.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -327.99% | -110.79% | |||
| Normalized Basic EPS | -328.42% | -88.66% | |||
| EPS Diluted | -327.99% | -110.79% | |||
| Normalized Diluted EPS | -328.42% | -88.66% | |||
| Average Basic Shares Outstanding | -54.51% | 7.22% | |||
| Average Diluted Shares Outstanding | -54.51% | 7.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||